Literature DB >> 20218800

Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with L- and D,L-methadone.

Dirk Wedekind1, Stefan Jacobs, Iris Karg, Christel Luedecke, Udo Schneider, Konrad Cimander, Pierre Baumann, Eckart Ruether, Wolfgang Poser, Ursula Havemann-Reinecke.   

Abstract

Sixty D,L- or L-methadone treated patients in maintenance therapy were interviewed for additional drug abuse and psychiatric comorbidity; 51.7% of the entire population had a comorbid Axis-I disorder, with a higher prevalence in females (P=0.05). Comorbid patients tended to have higher abuse of benzodiazepines, alcohol, cannabis, and cocaine, but not of heroin. They had received a significantly lower D,L- (P<0.05) and L-methadone dose than non-comorbid subjects. The duration of maintenance treatment showed an inverse relationship to frequency of additional heroin intake (P<0.01). Patients with additional heroin intake over the past 30 days had been treated with a significantly lower L-methadone dosage (P<0.05) than patients without. Axis-I comorbidity appears to be decreased when relatively higher dosages of D,L- (and L-methadone) are administered; comorbid individuals, however, were on significantly lower dosages. Finally, L-, but not D,L-methadone seems to be more effective in reducing additional heroin abuse.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218800     DOI: 10.3109/15622970802176487

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  7 in total

1.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

2.  Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

Authors:  Petra Jacobs; Alfonso Ang; Maureen P Hillhouse; Andrew J Saxon; Suzanne Nielsen; Paul G Wakim; Barbara E Mai; Larissa J Mooney; Jennifer S Potter; Jack D Blaine
Journal:  Am J Addict       Date:  2015-09-24

3.  Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.

Authors:  Amit Chakrabarti; George E Woody; Margaret L Griffin; Geetha Subramaniam; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2009-11-30       Impact factor: 4.492

4.  Experience of social discrimination correlates with neurometabolism: a pilot study in heroin addicts.

Authors:  Ulrich Frischknecht; Derik Hermann; Milena Heinrich; Mareen Hoerst; Wolfgang Weber-Fahr; Sabine Vollstädt-Klein; Falk Kiefer; Karl Mann; Gabriele Ende
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-09       Impact factor: 5.270

Review 5.  Opioids and Sickle Cell Disease: From Opium to the Opioid Epidemic.

Authors:  Samir K Ballas
Journal:  J Clin Med       Date:  2021-01-23       Impact factor: 4.241

6.  How I Treat Acute and Persistent Sickle Cell Pain.

Authors:  Samir K Ballas
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

7.  Substance Use, Hospitalizations, and Co-Occurring Disorders among Patients Transferred from a Needle Exchange Program to Opioid Maintenance Treatment.

Authors:  Martin Bråbäck; Anna Brantefors; Johan Franck; Louise Brådvik; Pernilla Isendahl; Suzan Nilsson; Katja Troberg; Anders Håkansson
Journal:  Int J Environ Res Public Health       Date:  2022-01-08       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.